LTC2662091I2 - Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui - Google Patents

Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Info

Publication number
LTC2662091I2
LTC2662091I2 LTPA2021506C LTPA2021506C LTC2662091I2 LT C2662091 I2 LTC2662091 I2 LT C2662091I2 LT PA2021506 C LTPA2021506 C LT PA2021506C LT PA2021506 C LTPA2021506 C LT PA2021506C LT C2662091 I2 LTC2662091 I2 LT C2662091I2
Authority
LT
Lithuania
Prior art keywords
treatment
inflammatory diseases
selectin antibodies
selectin
antibodies
Prior art date
Application number
LTPA2021506C
Other languages
English (en)
Original Assignee
Novartis Ag
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Oklahoma Medical Research Foundation filed Critical Novartis Ag
Publication of LTPA2021506I1 publication Critical patent/LTPA2021506I1/lt
Publication of LTC2662091I2 publication Critical patent/LTC2662091I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2021506C 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui LTC2662091I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
PCT/US2007/024692 WO2008069999A2 (en) 2006-12-01 2007-11-30 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
EP07867601A EP2097105A4 (en) 2006-12-01 2007-11-30 ANTI-P SELEKTIN ANTIBODIES AND METHOD FOR THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES

Publications (2)

Publication Number Publication Date
LTPA2021506I1 LTPA2021506I1 (lt) 2021-05-10
LTC2662091I2 true LTC2662091I2 (lt) 2022-10-10

Family

ID=39492818

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
LTPA2021506C LTC2662091I2 (lt) 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Country Status (11)

Country Link
US (2) US8377440B2 (lt)
EP (3) EP3501538A1 (lt)
CY (2) CY1121072T1 (lt)
DK (1) DK2662091T3 (lt)
ES (1) ES2699273T3 (lt)
HU (3) HUE041957T2 (lt)
LT (2) LT2662091T (lt)
PL (1) PL2662091T3 (lt)
PT (1) PT2662091T (lt)
SI (1) SI2662091T1 (lt)
WO (1) WO2008069999A2 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
SI2662091T1 (sl) * 2006-12-01 2019-01-31 Novartis Ag Protitelesa proti P-selektinu in postopki za njihovo uporabo za zdravljenje vnetnih bolezni
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
HUE037992T2 (hu) * 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
US10307487B2 (en) 2013-07-09 2019-06-04 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3595645A1 (en) 2017-03-15 2020-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
MX421249B (es) * 2017-05-10 2025-02-10 Wistar Inst Constructos de anticuerpos de ácidos nucleicos optimizados
EP3642631B1 (en) 2017-06-20 2022-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for identifying whether patients with acute decompensated heart failure (adhf) exhibit a hypercoagulable state
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
KR20210003086A (ko) 2018-03-08 2021-01-11 노파르티스 아게 항-p-셀렉틴 항체의 용도
US20220306749A1 (en) 2019-06-07 2022-09-29 Novartis Ag Use of an Anti-P-selectin Antibody
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
US20220324983A1 (en) * 2019-08-08 2022-10-13 Novartis Ag Use of the anti-p-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
MY209141A (en) 2019-10-30 2025-06-24 Novartis Ag Crizanlizumab containing antibody formulation
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DK0606391T3 (da) 1991-09-30 1999-05-03 Biogen Inc Inhibering af karforsnævring under anvendelse af anti-PADGEM-antistoffer
ES2152251T3 (es) 1992-04-30 2001-02-01 Genentech Inc Variantes del dominio lectina de la selectina.
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
ES2197150T3 (es) * 1992-05-05 2004-01-01 Aeres Biomedical Limited Anticuerpos contra p-selectina y sus utilizaciones.
WO1994025067A1 (en) 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10504527A (ja) * 1994-06-03 1998-05-06 センター・フォー・ブラッド・リサーチ・インコーポレーテッド アテローム性動脈硬化の治療法および防止法
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AU6173501A (en) 2000-05-19 2001-12-03 Blood Res Center Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP1542704A1 (en) * 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
SI2662091T1 (sl) * 2006-12-01 2019-01-31 Novartis Ag Protitelesa proti P-selektinu in postopki za njihovo uporabo za zdravljenje vnetnih bolezni
WO2009140623A2 (en) 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
HUE037992T2 (hu) 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására

Also Published As

Publication number Publication date
EP2662091A2 (en) 2013-11-13
EP2097105A4 (en) 2010-09-15
HUS2100015I1 (hu) 2021-05-28
HUS2100011I1 (hu) 2021-05-28
ES2699273T3 (es) 2019-02-08
LT2662091T (lt) 2018-12-10
WO2008069999A2 (en) 2008-06-12
US20110243926A1 (en) 2011-10-06
EP2662091A3 (en) 2014-03-12
US8377440B2 (en) 2013-02-19
DK2662091T3 (en) 2018-12-17
CY2021009I2 (el) 2021-12-31
US9556266B2 (en) 2017-01-31
US20140072551A1 (en) 2014-03-13
PL2662091T3 (pl) 2019-05-31
LTPA2021506I1 (lt) 2021-05-10
HUE041957T2 (hu) 2019-06-28
SI2662091T1 (sl) 2019-01-31
CY2021009I1 (el) 2021-10-15
WO2008069999A3 (en) 2008-12-04
EP3501538A1 (en) 2019-06-26
CY1121072T1 (el) 2019-12-11
PT2662091T (pt) 2018-12-03
EP2662091B1 (en) 2018-08-22
EP2097105A2 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
LTC2662091I2 (lt) Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
LTC2474557I2 (lt) Anti-cd79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
LTC2152290I2 (lt) Anti-il-5 antikūnų skyrimo būdai
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
CY2017039I2 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
CR10679A (es) Novel anti-cd38 antibodies for the treatment of cancer
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
FI20075738L (fi) Elimen valaiseminen
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
EP2154148A4 (en) SHORTENED L1 PROTEIN OF THE HUMAN PAPILLOMA VIRUS 11
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
DK2328553T3 (da) Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
DK2182007T3 (da) Fremgangsmåde til fremstilling af humant G-CSF
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
EP2281575A4 (en) ANTIBODIES FOR THE TREATMENT OF CANCER
FI20085333L (fi) Aktuaattorin äänikentän suuntaaminen
DK2224934T3 (da) Anvendelse af osteoblaster til behandling af inflammatoriske rheumatiske sygdomme
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases